Neumora Therapeutics, Inc. - NMRA
Ownership (Schedule 13D / 13G) · latest 50 filings
· Back to all files
Visible: 0
| Filed | Form | Reporting person | Percent | Shares | SEC |
|---|---|---|---|---|---|
| Apr 01, 2026 | SCHEDULE 13D/A | — | — | — | View |
| Feb 19, 2026 | SCHEDULE 13G | Invus Public Equities, L.P. | 4.9% | 8,172,814 | View |
| Feb 19, 2026 | SCHEDULE 13G | Invus Public Equities Advisors, LLC | 4.9% | 8,172,814 | View |
| Feb 19, 2026 | SCHEDULE 13G | Invus Global Management, LLC | 4.9% | 8,172,814 | View |
| Feb 19, 2026 | SCHEDULE 13G | Siren, L.L.C. | 4.9% | 8,172,814 | View |
| Feb 19, 2026 | SCHEDULE 13G | Avicenna Life Sci Master Fund LP | 0.5% | 825,008 | View |
| Feb 19, 2026 | SCHEDULE 13G | Avicenna Life Sci Master GP LLC | 0.5% | 825,008 | View |
| Feb 19, 2026 | SCHEDULE 13G | Ulys, L.L.C. | 0.5% | 825,008 | View |
| Feb 19, 2026 | SCHEDULE 13G | Raymond Debbane | 5.4% | 8,997,822 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | K2 HealthVentures Equity Trust LLC | 5.01% | 8,997,035 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Parag Shah | 5.01% | 8,997,035 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Anup Arora | 5.01% | 8,997,035 | View |
| Oct 29, 2025 | SCHEDULE 13D/A | — | — | — | View |
Percent = "% of class represented by amount beneficially owned" for this reporting person in the filed 13D/13G.
Shares = reported beneficial ownership amount for the same row (not portfolio shares from 13F).
Amendments (/A) can repeat the same holder over time, so rows should not be summed.
Extraction is best-effort from filing text and can be missing or noisy; verify exact figures via the SEC link in each row.